Related Experiment Video
Updated: Jun 12, 2026
06:34
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
Published on: March 27, 2017
Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide
Marco Gobbi1, Francesca Re, Mara Canovi
1Department of Biochemistry and Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milano, Italy.
Biomaterials
|June 18, 2010
Summary
Researchers developed novel nanoparticles targeting beta-amyloid (Abeta) aggregates, crucial in Alzheimer's disease (AD). These functionalized nanoparticles show high affinity for Abeta, offering potential for targeted AD diagnostics and therapeutics.
Area of Science:
- Nanomedicine
- Neuroscience
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by the abnormal accumulation of neurotoxic beta-amyloid (Abeta) peptides.
- Abeta aggregates, including oligomers, fibrils, and plaques, are implicated in AD pathogenesis and are potential therapeutic and diagnostic targets.
- Nanoparticles (NPs) offer promise as delivery vehicles for diagnostic probes and therapeutic agents in AD.
Purpose of the Study:
- To develop and characterize novel nanoparticles functionalized to specifically target and bind Abeta(1-42) aggregates.
- To evaluate the affinity and specificity of these functionalized NPs for Abeta aggregates.
- To explore the potential of these NPs as vectors for targeted delivery in AD.
Main Methods:
- Two types of NPs (liposomes and solid lipid nanoparticles) were synthesized and functionalized with anionic phospholipids (phosphatidic acid and cardiolipin).
- Binding interactions between functionalized NPs and Abeta(1-42) aggregates were assessed using ultracentrifugation and Surface Plasmon Resonance (SPR).
- Specificity was tested by evaluating NP binding to bovine serum albumin.
Main Results:
- PA/CL-functionalized NPs demonstrated significant interaction with Abeta(1-42) aggregates, unlike plain NPs.
- SPR studies revealed a very high affinity of PA/CL-functionalized NPs for Abeta(1-42) fibrils, attributed to multivalent interactions.
- The functionalized NPs showed no binding to bovine serum albumin, indicating high specificity for Abeta.
Conclusions:
- The developed PA/CL-functionalized NPs exhibit the highest reported affinity for Abeta aggregates.
- These NPs represent a promising platform for the targeted delivery of diagnostic and therapeutic agents for Alzheimer's disease.
- Further testing in relevant animal models is warranted to validate their therapeutic and diagnostic potential.
